Line is first from U-M accepted to the U.S. National Institutes of Health registry, now available for federally-funded research
The University of Michigan’s first human embryonic stem cell line will be placed on the U.S. National Institutes of Health’s registry, making the cells available for federally-funded research. It is the first of the stem cell lines derived at the University of Michigan to be placed on the registry.
The line, known as UM4-6, is a genetically normal line, derived in October 2010 from a cluster of about 30 cells removed from a donated five-day-old embryo roughly the size of the period
Image via Wikipedia
Dr. Robert Johnson, MD, of Neurosurgical Associates of San Antonio, is presenting at the 5th Annual Stem Cell Summit in New York on February 16, 2010. Dr. Johnson will be presenting his most recent data proving the efficacy of point of care adult stem cell therapies in spine surgery. Point of care technology utilizes the patient’s own cells derived from bone marrow to inhibit bone growth in spinal fusion procedures. Dr. Johnson believes promoting cell therapy utilizing the patient’s own cells will change the future landscape of medicine.
“The use of autologous stem cells is revolutionizing
Researchers using stem cells must work to make their treatments safer after a 17 year-old boy with a rare genetic disease in 2001 was cured with an embryonic stem cell transplant in Moscow, but then developed benign brain and spinal tumors four years later. According to ‘Plos Medicine’ magazine, Israeli doctors removed cancer from the boy, the tumors developed due to a stem cell treatment that he received.
Stem Cell Research Press Release
I released this press release on the Real Cost of Embryonic Stem Cell Research earlier this week and I just wanted to make sure you all saw it- the title was this:
Repair Stem Cell Institute Warns About Real Cost of Embryonic Stem Cell Research
RSCI’s Chairman expressed his concern that since […]
Aileen Anderson and Brian Cummings led the pre-clinical studies for the neural stem cell treatment
A therapy developed by Aileen Anderson and Brian Cummings of UC Irvine’s Sue & Bill Gross Stem Cell Research Center in collaboration with researchers at StemCells Inc. will be the basis of the world’s first clinical trial using human neural stem cells to treat spinal cord injury.
Swissmedic, the Swiss regulatory agency for therapeutic products, has authorized a Phase I/II clinical trial for chronic spinal cord injury, cases in which inflammation has stabilized and recovery has reached a